Fig. 5: The transcriptomic host response in control and 4′-FIU-treated AGMs challenged with LASV Togo.
From: Oral 4′-fluorouridine rescues nonhuman primates from advanced Lassa fever
a, Naive clustering via PCA for control (infected, untreated, n = 6) and infected 4′-FIU-treated AGMs (n = 5). b, Total significantly upregulated and downregulated genes at each disease stage compared to baseline for control and treated monkeys. c, Total significant DEGs comparing control and treated monkeys at each disease stage. d, Volcano plot comparing control monkeys at late time points post-infection versus transitional time points in treated monkeys. Significance testing of differential expression was performed using limma58, including a Benjamini–Hochberg-corrected false discovery rate P value. The raw P value was calculated by testing whether the log2-transformed fold change differs from zero using a two-sided test. e, Cell-type deconvolution for late controls versus transitional treated samples. In box plots, the bottom edge of the box represents the 25% quartile, the middle line represents the median (50%), the top of the box represents the 75% quartile, and the whiskers extend to minimum and maximum values. Outliers are designated as at least 1.5× the interquartile range. Mean log2 CPM was calculated using the marker genes in Supplementary Data 1. f, Selected enriched functional and canonical pathways and upstream regulators of DEGs. The full list of pathways and upstream regulators can be found in Supplementary Data 1 file. *P ≤ 0.05, **P < 0.01.
